Omeros rises after laying out aHUS therapy plans

Omeros Corp. (NASDAQ:OMER) gained $2.08 (16%) to $15.07 on Tuesday after providing an update on its Phase III and regulatory submission plans for OMS721 to treat atypical hemolytic uremic syndrome (aHUS) following a meeting with FDA.

The company said it will conduct only one Phase III trial of OMS721 to treat patients with aHUS. It plans to start enrolling the single-arm, open-label trial this year. aHUS is a rare and chronic blood disease that can lead to renal failure. ...